MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors
Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis,...
Gespeichert in:
Veröffentlicht in: | Human pathology 1998-12, Vol.29 (12), p.1420-1427 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1427 |
---|---|
container_issue | 12 |
container_start_page | 1420 |
container_title | Human pathology |
container_volume | 29 |
creator | Abramovich, Caroline M Prayson, Richard A |
description | Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas (
n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism (
n = 10) being the most frequent. The aggressive tumors (
n = 29; mean age, 61 years) were characterized by nuclear pleomorphism (
n = 28), mitoses (
n = 20), necrosis (
n = 16), loss of pattern (
n = 16), prominent nucleoli (
n = 6), and hypervascularity/hemosiderin deposition (
n = 5). Malignant tumors (
n = 24; mean age, 59 years) were characterized by nuclear pleomorphism (
n = 22), mitoses (
n = 21), loss of pattern (
n = 21), necrosis (
n = 21), nucleoli (
n = 17), and hypervascularity/hemosiderin deposition (
n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli (
P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with
P values of |
doi_str_mv | 10.1016/S0046-8177(98)90010-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69103557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817798900107</els_id><sourcerecordid>69103557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</originalsourceid><addsrcrecordid>eNqFkFuL1TAQgIMo63H1JyzkQUTBapI2beKLrIuXhRUf1EcJ6WRaIm26ZtqF_ffm7Dmsjz7NMPPNhY-xMyneSCHbt9-FaNrKyK57ac0rK4QUVfeA7aSuVWVqqx6y3T3ymD0h-l0YqRt9wk6sabVR3Y79-nr5oZJ88j1OMY08phABqUTeY4pjes39OGYkijdY8hT47KdS92nlcyHSGJfZ0zt-zmndwi1fBm4FX7d5yfSUPRr8RPjsGE_Zz08ff1x8qa6-fb68OL-qoDZ2rXSQne4hQK1QgfFeiaERplFdgN4EKaysRR3Ag-qVwUHJRnvdqR5arXsN9Sl7cdh7nZc_G9Lq5kiA0-QTLhu51kpRa90VUB9AyAtRxsFd5zj7fOukcHut7k6r2ztz1rg7rW4_d3Y8sPUzhvupo8fSf37sewI_DdkniPRvedsIa1XB3h8wLDJuImZHEDEBhpgRVheW-J9H_gI0npLx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69103557</pqid></control><display><type>article</type><title>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Abramovich, Caroline M ; Prayson, Richard A</creator><creatorcontrib>Abramovich, Caroline M ; Prayson, Richard A</creatorcontrib><description>Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas (
n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism (
n = 10) being the most frequent. The aggressive tumors (
n = 29; mean age, 61 years) were characterized by nuclear pleomorphism (
n = 28), mitoses (
n = 20), necrosis (
n = 16), loss of pattern (
n = 16), prominent nucleoli (
n = 6), and hypervascularity/hemosiderin deposition (
n = 5). Malignant tumors (
n = 24; mean age, 59 years) were characterized by nuclear pleomorphism (
n = 22), mitoses (
n = 21), loss of pattern (
n = 21), necrosis (
n = 21), nucleoli (
n = 17), and hypervascularity/hemosiderin deposition (
n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli (
P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with
P values of <.0001 (benign v aggressive) and .0012 (aggressive
v malignant). Mean MIB-1 LIs for recurrent versus nonrecurrent tumors were 7.1% (range, 0 to 32.5%) versus 3.8% (range, 0 to 20.9%) (
P = .32). The mean MIB-1 LI for patients who were alive with or without tumor was 6.2% (range, 0 to 32.5%) versus a mean MIB-1 LI of 14.2% (range, 2.8% to 32.5%) for patients who died of or with tumor (
P = .0013). In conclusion, (1) There is a statistically significant difference in the increasing MIB-1 LI means between benign, aggressive, and malignant meningiomas and between patients who were alive versus those who died; (2) there is some overlap in MIB-1 LI ranges between groups, which warrants caution in interpreting an individual MIB-1 LI in a given tumor.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/S0046-8177(98)90010-7</identifier><identifier>PMID: 9865827</identifier><identifier>CODEN: HPCQA4</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; aggressive meningioma ; Antigens, Nuclear ; atypical meningioma ; Biological and medical sciences ; Biomarkers ; Female ; Humans ; Immunoenzyme Techniques ; Ki-67 Antigen ; Male ; malignant meningioma ; Medical sciences ; Meningeal Neoplasms - metabolism ; Meningeal Neoplasms - mortality ; Meningeal Neoplasms - pathology ; meningioma ; Meningioma - metabolism ; Meningioma - mortality ; Meningioma - pathology ; MIB-1 antibody ; Middle Aged ; Mitotic Index ; Neoplasm Invasiveness - pathology ; Neoplasm Recurrence, Local - pathology ; Neurology ; Nuclear Proteins - metabolism ; Retrospective Studies ; Survival Analysis ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Human pathology, 1998-12, Vol.29 (12), p.1420-1427</ispartof><rights>1998</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</citedby><cites>FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0046817798900107$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1640992$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9865827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abramovich, Caroline M</creatorcontrib><creatorcontrib>Prayson, Richard A</creatorcontrib><title>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas (
n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism (
n = 10) being the most frequent. The aggressive tumors (
n = 29; mean age, 61 years) were characterized by nuclear pleomorphism (
n = 28), mitoses (
n = 20), necrosis (
n = 16), loss of pattern (
n = 16), prominent nucleoli (
n = 6), and hypervascularity/hemosiderin deposition (
n = 5). Malignant tumors (
n = 24; mean age, 59 years) were characterized by nuclear pleomorphism (
n = 22), mitoses (
n = 21), loss of pattern (
n = 21), necrosis (
n = 21), nucleoli (
n = 17), and hypervascularity/hemosiderin deposition (
n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli (
P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with
P values of <.0001 (benign v aggressive) and .0012 (aggressive
v malignant). Mean MIB-1 LIs for recurrent versus nonrecurrent tumors were 7.1% (range, 0 to 32.5%) versus 3.8% (range, 0 to 20.9%) (
P = .32). The mean MIB-1 LI for patients who were alive with or without tumor was 6.2% (range, 0 to 32.5%) versus a mean MIB-1 LI of 14.2% (range, 2.8% to 32.5%) for patients who died of or with tumor (
P = .0013). In conclusion, (1) There is a statistically significant difference in the increasing MIB-1 LI means between benign, aggressive, and malignant meningiomas and between patients who were alive versus those who died; (2) there is some overlap in MIB-1 LI ranges between groups, which warrants caution in interpreting an individual MIB-1 LI in a given tumor.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>aggressive meningioma</subject><subject>Antigens, Nuclear</subject><subject>atypical meningioma</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Ki-67 Antigen</subject><subject>Male</subject><subject>malignant meningioma</subject><subject>Medical sciences</subject><subject>Meningeal Neoplasms - metabolism</subject><subject>Meningeal Neoplasms - mortality</subject><subject>Meningeal Neoplasms - pathology</subject><subject>meningioma</subject><subject>Meningioma - metabolism</subject><subject>Meningioma - mortality</subject><subject>Meningioma - pathology</subject><subject>MIB-1 antibody</subject><subject>Middle Aged</subject><subject>Mitotic Index</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neurology</subject><subject>Nuclear Proteins - metabolism</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkFuL1TAQgIMo63H1JyzkQUTBapI2beKLrIuXhRUf1EcJ6WRaIm26ZtqF_ffm7Dmsjz7NMPPNhY-xMyneSCHbt9-FaNrKyK57ac0rK4QUVfeA7aSuVWVqqx6y3T3ymD0h-l0YqRt9wk6sabVR3Y79-nr5oZJ88j1OMY08phABqUTeY4pjes39OGYkijdY8hT47KdS92nlcyHSGJfZ0zt-zmndwi1fBm4FX7d5yfSUPRr8RPjsGE_Zz08ff1x8qa6-fb68OL-qoDZ2rXSQne4hQK1QgfFeiaERplFdgN4EKaysRR3Ag-qVwUHJRnvdqR5arXsN9Sl7cdh7nZc_G9Lq5kiA0-QTLhu51kpRa90VUB9AyAtRxsFd5zj7fOukcHut7k6r2ztz1rg7rW4_d3Y8sPUzhvupo8fSf37sewI_DdkniPRvedsIa1XB3h8wLDJuImZHEDEBhpgRVheW-J9H_gI0npLx</recordid><startdate>19981201</startdate><enddate>19981201</enddate><creator>Abramovich, Caroline M</creator><creator>Prayson, Richard A</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981201</creationdate><title>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</title><author>Abramovich, Caroline M ; Prayson, Richard A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>aggressive meningioma</topic><topic>Antigens, Nuclear</topic><topic>atypical meningioma</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Ki-67 Antigen</topic><topic>Male</topic><topic>malignant meningioma</topic><topic>Medical sciences</topic><topic>Meningeal Neoplasms - metabolism</topic><topic>Meningeal Neoplasms - mortality</topic><topic>Meningeal Neoplasms - pathology</topic><topic>meningioma</topic><topic>Meningioma - metabolism</topic><topic>Meningioma - mortality</topic><topic>Meningioma - pathology</topic><topic>MIB-1 antibody</topic><topic>Middle Aged</topic><topic>Mitotic Index</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neurology</topic><topic>Nuclear Proteins - metabolism</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abramovich, Caroline M</creatorcontrib><creatorcontrib>Prayson, Richard A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abramovich, Caroline M</au><au>Prayson, Richard A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>1998-12-01</date><risdate>1998</risdate><volume>29</volume><issue>12</issue><spage>1420</spage><epage>1427</epage><pages>1420-1427</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><coden>HPCQA4</coden><abstract>Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas (
n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism (
n = 10) being the most frequent. The aggressive tumors (
n = 29; mean age, 61 years) were characterized by nuclear pleomorphism (
n = 28), mitoses (
n = 20), necrosis (
n = 16), loss of pattern (
n = 16), prominent nucleoli (
n = 6), and hypervascularity/hemosiderin deposition (
n = 5). Malignant tumors (
n = 24; mean age, 59 years) were characterized by nuclear pleomorphism (
n = 22), mitoses (
n = 21), loss of pattern (
n = 21), necrosis (
n = 21), nucleoli (
n = 17), and hypervascularity/hemosiderin deposition (
n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli (
P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with
P values of <.0001 (benign v aggressive) and .0012 (aggressive
v malignant). Mean MIB-1 LIs for recurrent versus nonrecurrent tumors were 7.1% (range, 0 to 32.5%) versus 3.8% (range, 0 to 20.9%) (
P = .32). The mean MIB-1 LI for patients who were alive with or without tumor was 6.2% (range, 0 to 32.5%) versus a mean MIB-1 LI of 14.2% (range, 2.8% to 32.5%) for patients who died of or with tumor (
P = .0013). In conclusion, (1) There is a statistically significant difference in the increasing MIB-1 LI means between benign, aggressive, and malignant meningiomas and between patients who were alive versus those who died; (2) there is some overlap in MIB-1 LI ranges between groups, which warrants caution in interpreting an individual MIB-1 LI in a given tumor.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9865827</pmid><doi>10.1016/S0046-8177(98)90010-7</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0046-8177 |
ispartof | Human pathology, 1998-12, Vol.29 (12), p.1420-1427 |
issn | 0046-8177 1532-8392 |
language | eng |
recordid | cdi_proquest_miscellaneous_69103557 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adolescent Adult Aged Aged, 80 and over aggressive meningioma Antigens, Nuclear atypical meningioma Biological and medical sciences Biomarkers Female Humans Immunoenzyme Techniques Ki-67 Antigen Male malignant meningioma Medical sciences Meningeal Neoplasms - metabolism Meningeal Neoplasms - mortality Meningeal Neoplasms - pathology meningioma Meningioma - metabolism Meningioma - mortality Meningioma - pathology MIB-1 antibody Middle Aged Mitotic Index Neoplasm Invasiveness - pathology Neoplasm Recurrence, Local - pathology Neurology Nuclear Proteins - metabolism Retrospective Studies Survival Analysis Tumors of the nervous system. Phacomatoses |
title | MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T19%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MIB-1%20labeling%20indices%20in%20benign,%20aggressive,%20and%20malignant%20meningiomas:%20A%20study%20of%2090%20tumors&rft.jtitle=Human%20pathology&rft.au=Abramovich,%20Caroline%20M&rft.date=1998-12-01&rft.volume=29&rft.issue=12&rft.spage=1420&rft.epage=1427&rft.pages=1420-1427&rft.issn=0046-8177&rft.eissn=1532-8392&rft.coden=HPCQA4&rft_id=info:doi/10.1016/S0046-8177(98)90010-7&rft_dat=%3Cproquest_cross%3E69103557%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69103557&rft_id=info:pmid/9865827&rft_els_id=S0046817798900107&rfr_iscdi=true |